Trial Profile
Pivotal pharmacokinetic clinical study for Riluzole Oral Soluble Film
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 25 Jan 2018
Price :
$35
*
At a glance
- Drugs Riluzole (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Pharmacokinetics
- 30 Nov 2017 According to a Aquestive Therapeutics media release, MonoSol Rx changed its name to Aquestive Therapeutics
- 09 Jan 2017 New trial record
- 05 Jan 2017 According to a MonoSol Rx media release, the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for Riluzole Oral Soluble Film (Riluzole OSF) for the treatment of Amyotrophic Lateral Sclerosis.